000 03949nam a22005775i 4500
001 978-981-97-7380-0
003 DE-He213
005 20251030113247.0
007 cr nn 008mamaa
008 241026s2024 si | s |||| 0|eng d
020 _a9789819773800
_9978-981-97-7380-0
024 7 _a10.1007/978-981-97-7380-0
_2doi
050 4 _aRM300-666
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
072 7 _aMKG
_2thema
245 1 0 _aAngiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers
_h[electronic resource] :
_bA Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview /
_cedited by Mukesh Nandave.
250 _a1st ed. 2024.
264 1 _aSingapore :
_bSpringer Nature Singapore :
_bImprint: Springer,
_c2024.
300 _aXIV, 602 p. 25 illus.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aChapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS) -- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders -- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs) -- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin–angiotensin system -- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients -- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure -- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients -- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease -- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients -- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.
520 _aThe auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.
650 0 _aPharmacology.
_967844
650 0 _aPharmacovigilance.
_974275
650 0 _aMedicine
_xResearch.
_962598
650 0 _aBiology
_xResearch.
_965629
650 0 _aClinical biochemistry.
_967825
650 0 _aTherapeutics.
_970087
650 1 4 _aPharmacology.
_967844
650 2 4 _aDrug Safety and Pharmacovigilance.
_974276
650 2 4 _aBiomedical Research.
_965633
650 2 4 _aMedical Biochemistry.
_967828
650 2 4 _aTherapeutics.
_970087
700 1 _aNandave, Mukesh.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_974724
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9789819773794
776 0 8 _iPrinted edition:
_z9789819773817
776 0 8 _iPrinted edition:
_z9789819773824
856 4 0 _uhttps://doi.org/10.1007/978-981-97-7380-0
912 _aZDB-2-SME
912 _aZDB-2-SXM
999 _c64518
_d64518